



PERÚ

Ministerio
de Salud

Instituto Nacional
de Salud

Oficina General de
Investigación y
Transferencia

COMMUNICATION N° 006 -2023-DIIS/INS

Publication date on the REPEC website: Friday, December 15, 2023

Through this statement, the Directorate of Health Research and Innovation – DIIS, informs that the optimization work on the REPEC platform continues, with the aim of receiving and managing information from clinical trials on a single platform, so You are informed that the Peruvian Registry of Clinical Trials will be closed –

REPECv1 for entry: progress reports, center final reports, national final reports and international final reports, but they will remain in REPEC v1 for consultation.

In this sense, we request that as of Monday, **December 18, 2023**, the presentation of the reports must be entered through the REPECv2 platform <https://repec.ins.gob.pe/> _____

Finally, you are reminded that all requests must be registered through the Peruvian Registry of Clinical Trials – REPECv2 and notified by the [Virtual Parties Table \(MPV\)](#), which is the official channel for receiving documents and will allow you to follow up. of their procedures.

If you have any questions or problems about the REPECv2 System, you can contact Engineer Jenny Parillo at Telephone (+511) 7480000 annex 2616 or at Cell 984108368, email jparillo@ins.gob.pe

Health Research and Innovation Directorate – DIIS
National Institute of Health